ealthcare should make people’s lives better. That fact can hardly be contested. Yet for some patients with rare diseases, commercial interests are dictating who gets to access life-saving treatment and who doesn’t. Pharmaceutical companies have long been driven by global demand and the potential for the highest profits. In the past two decades, the market has exploded: pharma revenues worldwide. For patients with common conditions, this investment in healthcare can only be good news.
Investment decisions by pharmaceutical companies are complex and influenced by many factors, including policy and regulatory frameworks, upfront costs and clinical feasibility. Even if a drug is proven to be an effective treatment for disease, is shown to be safe and is expected to generate millions of pounds a year, sometimes it’s not enough for a company to justify the investment.
The good news for women: a drug to limit hot flushes. The bad: it could cost you £430 a month | Devi SridharWe are also seeing many drugs for treating rare diseases being dropped or paused in their development because of concerns over their commercial viability.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: GuardianAus - 🏆 1. / 98 Read more »